Is Targeted Therapy the Same as Immunotherapy?

No. Targeted therapy and immunotherapy are two different kinds of modern cancer treatment, though the names are often confused. One goes after the cancer cell’s own machinery, while the other recruits the body’s immune system to do the attacking.¹ The line blurs in practice, since some targeted drugs also help the immune system, and doctors increasingly pair the two.²

How Targeted Therapy and Immunotherapy Work Differently

Targeted drugs block specific molecular pathways that a tumor relies on to grow and survive.³ Many cancers are driven by a particular genetic change, and a drug can be designed to block exactly that.⁴ The aim is to hit cancer cells while doing little damage to normal cells.⁵

Immunotherapy works on your immune system rather than on the tumor directly. The most common kind, called checkpoint inhibitors, blocks natural brakes on immune cells called T cells.⁶ Proteins named PD-1 and CTLA-4 normally hold T cells back, and tumors exploit them.⁷ Blocking those brakes reactivates the T cells so they attack the cancer.⁸ Both differ from chemotherapy, which kills fast-dividing cells broadly, healthy ones included.

Targeted drugs are matched to a particular molecular driver, so two people with the same cancer type can respond very differently. Immunotherapy depends on whether immune cells can see the tumor as abnormal, so a tumor hidden from T cells may not respond even when the brakes are released.

The names on your treatment plan offer clues. Drug names ending in -inib are usually targeted pills, such as gefitinib. Names ending in -mab are antibodies and can be either type, so the ending is only a rough clue. Pembrolizumab, for example, is a checkpoint immunotherapy, not a targeted pill. If you’re unsure, ask your oncologist which category each drug on your plan belongs to.

Treatments That Are a Bit of Both

Many antibody drugs attach to a marker on the surface of the cancer cell.⁹ Their tail end then signals immune cells to destroy the marked cell.¹⁰ Not every antibody that sticks to a cancer cell works this way. Some mainly block a growth signal, and how much immune activity contributes varies from drug to drug. Because the labels overlap, asking what your specific drug does is more informative than asking which category it falls into.

Newer engineered treatments push this further. Antibody-drug conjugates carry a chemotherapy payload straight to cancer cells, as trastuzumab deruxtecan does in some breast cancers.¹¹ Bispecific antibodies grab a cancer cell and a T cell at once, giving deep responses in some blood cancers.¹² CAR-T therapy reengineers a patient’s own T cells with an antibody-like receptor that seeks out the cancer.¹³

How Doctors Decide Which One You Get

Tumor testing matters differently for each treatment. Targeted drugs work in groups of patients whose tumors carry a specific genetic change.¹⁴ So a tumor test result for targeted therapy, called a biomarker, is usually a yes or no. Immunotherapy biomarkers are different: they sit on a sliding scale, can vary across the tumor and over time, and depend on many factors.¹⁵ An immunotherapy marker suggests your odds rather than giving a clear answer.¹⁶

A clear match often points directly to a drug that was studied in people with that same change. When no matching change is found, targeted pills for that driver are usually not expected to help, so the test also spares people a treatment unlikely to work. Some tests look for many genetic changes at once, so one sample can show several possible matches or none. Testing is often done on the biopsy tissue already taken, and results can take a week or more.

Immune markers are less clear-cut. They are usually reported as a level, such as how many tumor cells show a certain protein, and the cutoff used to call something high is a line drawn for convenience. A tumor can differ from one spot to another, so a small biopsy may not represent the whole cancer. Some people with a low marker still benefit from immunotherapy, and some with a high marker do not.

Useful questions for your results: Does my tumor have a mutation with a matching drug? What does my immune marker level mean for my odds? Might retesting help later if the cancer changes?

How Fast Each Works and How Long It Lasts

Targeted drugs often shrink tumors quickly by blocking the driver.¹⁷ Early response rates can be high and survival often improves.¹⁸ But cancer often becomes resistant, which limits how long the benefit lasts.¹⁹ Some tumor cells change the target, and others switch to backup growth pathways.²⁰

In daily life, a good response can mean symptoms easing within weeks, with scans showing shrinkage fairly early. The drug is typically continued as long as it keeps working and side effects are manageable, so treatment may not have a set end date. Stopping a pill on your own because you feel better can let the cancer regrow, so changes should go through your team.

Resistance shows up when scans reveal the tumor growing again after shrinking. It doesn’t mean the first drug failed. Doctors may retest the tumor to look for a new change, and another targeted drug or a different approach may follow.

Immunotherapy often takes longer to show a response.²¹ Once it works, the effect tends to last, sometimes years after treatment stops.²² That lasting benefit happens in only a minority of patients.²³ Being told immunotherapy is an option is not a promise it will work for you.

Tumors can also respond in unusual ways, unlike patterns seen with other treatments.²⁴ Early scans may look unchanged or even worse, and doctors may wait for a follow-up scan before deciding. Ask how your team will judge whether it is working.

Side Effects of Each Treatment

Common targeted therapy side effects include rash, diarrhea, high blood pressure, an underactive thyroid, liver problems and skin lightening.²⁵ Some come from blocking the same target in healthy tissue.²⁶ Drugs that block blood vessel growth signals are especially linked to high blood pressure,²⁷ so regular blood pressure checks matter during treatment with them.

Because effects follow the molecule being blocked, two targeted pills can feel very different. Rash and diarrhea are common with drugs that block growth signals which healthy skin and gut cells also use. Liver problems and thyroid changes usually show up on blood tests, which is why scheduled lab work matters even when you feel fine. Many of these effects can be managed with creams, anti-diarrhea medicine or a dose adjustment, so tell your team early instead of quietly stopping the drug.

Checkpoint drugs can let the immune system attack healthy tissue.²⁸ This causes immune-related side effects that resemble autoimmune diseases.²⁹ Report any new symptom quickly, even weeks after a dose. These effects can look like ongoing diarrhea (bowel inflammation), a new cough or breathlessness (lung inflammation), or fatigue and weight changes (thyroid problems). Rash and itching are common and usually mild.

Immune side effects can affect almost any organ, because activated T cells are not limited to the tumor. They can begin weeks or even months after a dose, and occasionally after treatment has ended, so a new symptom later on still deserves a call. Treatment is often steroids or other medicines that calm the immune response, and the drug may be paused meanwhile. Most are manageable when caught early, but serious ones can develop quickly, so don’t wait to see if a symptom passes.

Using Targeted Therapy and Immunotherapy Together

The quick response of targeted therapy can combine with the lasting response of immunotherapy.³⁰ Some targeted drugs also make cancer cells more visible to the immune system.³¹ For example, drugs blocking blood vessel signals help T cells reach the tumor.³² Such combinations have worked well in some lung cancers,³³ and they show promise in advanced melanoma.³⁴

Timing and sequence matter. Combinations can be given at the same time, or a targeted pill can be used first and immunotherapy added or switched to later. The order is chosen based on the cancer type, the tumor test results and what has been studied. Giving both together does not automatically work better than either alone, which is why only certain pairings are used. Some raise the chance of side effects, such as liver inflammation, so teams may monitor blood tests closely.

For you, a combination may mean a pill plus an infusion, with side effects from both types possible together. Your team will watch for both kinds of problems. Ask whether a combination is standard for your cancer or part of a trial.

How They Are Given and What They Cost

Many targeted drugs are pills taken at home, often daily.³⁵ Pills can be missed, and food can affect how well they are absorbed.³⁶ Infusions, by contrast, are given in clinic, which makes dosing reliable and builds in regular checkups.³⁷

A pill puts more responsibility on you, including remembering doses and tracking refills. Some targeted drugs must be taken with food and others on an empty stomach, so check the instructions for your specific drug. Other medicines, supplements and even grapefruit can interact with certain targeted pills, so tell your pharmacist everything you take. If you miss a dose or vomit after taking one, ask your team what to do instead of doubling up.

Checkpoint infusions are often every few weeks, and each visit includes blood tests and checks.

Cost differs sharply. Six months of pembrolizumab cost nearly six times a typical monthly income in the US,³⁸ while a targeted pill such as gefitinib cost far less.³⁹ Ask about insurance coverage and assistance programs early. Coverage may require prior approval before starting, drug makers often run patient assistance programs, and hospital financial counselors can help.